Reports
Sale
Fibrotic Diseases Treatment Market Size, Share, Analysis: By Treatment Type: Medication, Organ Transplantation, Oxygen Therapy, Others; By Applications: Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, Others, By End User: Hospitals, Others; Regional Analysis; Supplier Landscape; 2024-2032
Fibrotic Diseases Treatment Market Outlook
The fibrotic diseases treatment market size is expected to grow at a CAGR of 7.8% during the forecast period of 2024-2032. The market is likely to be driven by the rising prevalence and incidence of fibrotic diseases, the growing demand for precision medicine, and heightened patient awareness across the 8 major markets.
Fibrotic Diseases Treatment Market Overview
Fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF) and scleroderma, are characterized by severe organ fibrosis. Progressive fibrosis can result in the thickening or scarring of the tissue. According to a study published in BMC Pulmonary Medicine in February 2023, the rate of idiopathic pulmonary fibrosis (IPF) has been increasing over time. The study found that the yearly prevalence rate of IPF increased from 7.50 to 23.20 per 100,000 individuals, and the yearly incidence rate increased from 3.56 to 7.91 per 100,000 individuals. The rising number of patients afflicted with this condition will fuel the fibrotic diseases treatment market growth in the forecast period.
In September 2023 , Boehringer Ingelheim initiated the clinical development of its first-of-its-kind IL-11 inhibitor antibody, BI 765423, through a Phase 1 study. The objective of the trial was to evaluate the treatment's safety, tolerance, and pharmacokinetics in fibrotic diseases. According to preclinical studies, anti-IL-11 treatment had the potential to halt and even reverse fibrosis in various fibrotic diseases. To bolster its fibrotic disease portfolio, Boehringer Ingelheim also partnered with Enleofen Bio Pte Ltd, a biotechnology company based in Singapore. The development of promising therapeutics is projected to fuel the fibrotic diseases treatment market demand in the coming years.
Significant drivers for market growth also include the rise in strategic partnerships among the key market players. In addition, the increased healthcare expenditure and growing geriatric population as also expected to contribute to the market value in the forecast period.
Fibrotic Diseases Treatment Market Trends
| Key Trends | Description |
| Antifibrotic Therapies | The development and approval of antifibrotic drugs have resulted in a significant advancement. Such therapeutics are offering the first specific treatments that can slow disease progression in conditions like idiopathic pulmonary fibrosis. |
| Targeted Molecular Therapies | Intensive research has led to the identification of molecular pathways involved in fibrosis. These therapies are targeting specific molecules or signals to prevent, halt, or reverse the fibrotic process. |
| Regenerative Medicine and Cell Therapy | Stem cell therapy and other regenerative approaches are being explored as potential treatments to repair and regenerate damaged tissues. These emerging technologies offer hope for improved patient outcomes in fibrotic diseases. |
| Precision Medicine | There is an increasing demand for precision medicine. Personalized treatments based on individual genetic makeup, disease phenotype, and other biomarkers hold promise to improve efficacy and reduce side effects. |
Fibrotic Diseases Treatment Market Segmentation
Market Breakup by Treatment Type
- Medication
- Organ Transplantation
- Oxygen Therapy
- Others
The market segmentation by treatment type comprises medication, organ transplantation, and oxygen therapy, among others. Medication options aim to slow disease progression and reduce symptoms by targeting inflammation and fibroblast activation. Organ transplantation may be necessary when fibrosis irreversibly damages vital organs. Oxygen therapy helps manage respiratory symptoms in fibrotic lung diseases.
Market Breakup by Applications
- Idiopathic Pulmonary Fibrosis
- Hepatic Cirrhosis
- Renal Fibrosis
- Cutaneous Fibrosis
- Others
On the basis of applications, the fibrotic diseases treatment market share includes idiopathic pulmonary fibrosis (IPF), hepatic cirrhosis, renal fibrosis, cutaneous fibrosis, and others. These diverse applications convey the scope of the treatment market across various organ systems.
Market Breakup by End User
- Hospitals
- Academic and research institutes
- Others
End users of the market are hospitals, academic, and research institutes, among others. Academic and research institutes significantly contribute to the development of innovative treatments and therapeutic approaches.
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
The segmentation based on the region covers the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. North America holds a substantial fibrotic diseases treatment market value which can be attributed to the rising geriatric population base in the region. Moreover, the high prevalence rate of fibrotic diseases and the presence of key market players are also boosting growth in this regional market.
Fibrotic Diseases Treatment Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Genentech, Inc.
- Boehringer Ingelheim International GmbH
- AbbVie Inc.
- Bristol-Myers Squibb Company
- BellBrook Labs
- Enveda Biosciences
- Gilead Sciences, Inc.
- KITHER BIOTECH S.R.L.
- Verona Pharma plc
- Alpine Immune Sciences
- Intercept Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Sandoz International GmbH
- Accord Healthcare
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Applications |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Fibrotic Diseases Treatment Market Report
- What are the emerging trends and developments shaping the future of the fibrotic diseases treatment market?
- Which treatment option dominates the market segment?
- What factors are driving or restraining the growth of the market?
- How is the market segmented by applications, end-users, and geographic regions?
- What are the pipeline developments and emerging therapies in the fibrotic diseases treatment market?
- How is the prevalence of fibrotic diseases projected to change in the future?
- Which is the most common fibrotic disease in terms of prevalence and how will it impact the market size?
- What key research initiatives will propel fibrotic diseases treatment market size during the forecast period?
- What are the unmet needs and opportunities in the market?
- Which country is poised to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- Which applications of the treatment market are expected to significantly impact the growth of the market?
- Which segment will have the highest impact on the market size in the coming years?
- How are academic and research institutes contributing to advancements in fibrotic diseases treatment?
- How are partnerships, collaborations, and mergers & acquisitions shaping the market dynamics?
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Fibrotic Diseases Treatment Market Overview – 8 Major Markets
3.1 Fibrotic Diseases Treatment Market Historical Value (2017-2023)
3.2 Fibrotic Diseases Treatment Market Forecast Value (2024-2032)
4 Fibrotic Diseases Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Fibrotic Diseases Epidemiology Scenario and Forecast – 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Fibrotic Diseases Epidemiology Scenario and Forecast (2017-2032)
6.3 EU-4 and United Kingdom Fibrotic Diseases Epidemiology Scenario and Forecast (2017-2032)
6.3.1 Germany Fibrotic Diseases Epidemiology Scenario and Forecast (2017-2032)
6.3.2 France Fibrotic Diseases Epidemiology Scenario and Forecast (2017-2032)
6.3.3 Italy Fibrotic Diseases Epidemiology Scenario and Forecast (2017-2032)
6.3.4 Spain Fibrotic Diseases Epidemiology Scenario and Forecast (2017-2032)
6.3.5 United Kingdom Fibrotic Diseases Epidemiology Scenario and Forecast (2017-2032)
6.4 Japan Fibrotic Diseases Epidemiology Scenario and Forecast (2017-2032)
6.5 India Fibrotic Diseases Epidemiology Scenario and Forecast (2017-2032)
7 Fibrotic Diseases Treatment Market Landscape – 8 Major Markets
7.1 Fibrotic Diseases Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Fibrotic Diseases Treatment: Product Landscape
7.2.1 Analysis by Treatment
7.2.2 Analysis by Applications
8 Fibrotic Diseases Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Fibrotic Diseases Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Fibrotic Diseases Treatment Market Segmentation (2017-2032) - 8 Major Markets
11.1 Fibrotic Diseases Treatment Market (2017-2032) by Treatment Type
11.1.1 Market Overview
11.1.2 Medication
11.1.3 Organ Transplantation
11.1.4 Oxygen Therapy
11.1.5 Others
11.2 Fibrotic Diseases Treatment Market (2017-2032) by Applications
11.2.1 Market Overview
11.2.2 Idiopathic Pulmonary Fibrosis
11.2.3 Hepatic Cirrhosis
11.2.4 Renal Fibrosis
11.2.5 Cutaneous Fibrosis
11.2.6 Others
11.3 Fibrotic Diseases Treatment Market (2017-2032) by End User
11.3.1 Market Overview
11.3.2 Hospitals
11.3.3 Academic and research institutes
11.3.4 Others
11.4 Fibrotic Diseases Treatment Market (2017-2032) by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
11.4.5 India
12 United States Fibrotic Diseases Treatment Market (2017-2032)
12.1 United States Fibrotic Diseases Treatment Market Historical Value (2017-2023)
12.2 United States Fibrotic Diseases Treatment Market Forecast Value (2024-2032)
12.3 United States Fibrotic Diseases Treatment Market (2017-2032) by Treatment Type
12.3.1 Market Overview
12.3.2 Medication
12.3.3 Organ Transplantation
12.3.4 Oxygen Therapy
12.3.5 Others
12.4 United States Fibrotic Diseases Treatment Market (2017-2032) by Applications
12.4.1 Market Overview
12.4.2 Idiopathic pulmonary fibrosis
12.4.3 Hepatic cirrhosis
12.4.4 Renal fibrosis
12.4.5 Cutaneous fibrosis
12.4.6 Others
13 EU-4 and United Kingdom Fibrotic Diseases Treatment Market (2017-2032)
13.1 EU-4 and United Kingdom Fibrotic Diseases Treatment Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Fibrotic Diseases Treatment Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Fibrotic Diseases Treatment Market (2017-2032) by Treatment Type
13.3.1 Market Overview
13.3.2 Medication
13.3.3 Organ Transplantation
13.3.4 Oxygen Therapy
13.3.5 Others
13.4 EU-4 and United Kingdom Fibrotic Diseases Treatment Market (2017-2032) by Applications
13.4.1 Market Overview
13.4.2 Idiopathic pulmonary fibrosis
13.4.3 Hepatic cirrhosis
13.4.4 Renal fibrosis
13.4.5 Cutaneous fibrosis
13.4.6 Others
14 Japan Fibrotic Diseases Treatment Market
14.1 Japan Fibrotic Diseases Treatment Market Historical Value (2017-2023)
14.2 Japan Fibrotic Diseases Treatment Market Forecast Value (2024-2032)
14.3 Japan Fibrotic Diseases Treatment Market (2017-2032) by Treatment Type
14.3.1 Market Overview
14.3.2 Medication
14.3.3 Organ Transplantation
14.3.4 Oxygen Therapy
14.3.5 Others
14.4 Japan Fibrotic Diseases Treatment Market (2017-2032) by Applications
14.4.1 Market Overview
14.4.2 Idiopathic pulmonary fibrosis
14.4.3 Hepatic cirrhosis
14.4.4 Renal fibrosis
14.4.5 Cutaneous fibrosis
14.4.6 Others
15 India Fibrotic Diseases Treatment Market
15.1 India Fibrotic Diseases Treatment Market (2017-2032) Historical Value (2017-2023)
15.2 India Fibrotic Diseases Treatment Market (2017-2032) Forecast Value (2024-2032)
15.3 India Fibrotic Diseases Treatment Market (2017-2032) by Treatment Type
15.3.1 Market Overview
15.3.2 Medication
15.3.3 Organ Transplantation
15.3.4 Oxygen Therapy
15.3.5 Others
15.4 India Fibrotic Diseases Treatment Market (2017-2032) by Applications
15.4.1 Market Overview
15.4.2 Idiopathic pulmonary fibrosis
15.4.3 Hepatic cirrhosis
15.4.4 Renal fibrosis
15.4.5 Cutaneous fibrosis
15.4.6 Others
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 Japan PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Genentech, Inc.
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Boehringer Ingelheim International GmbH
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 AbbVie Inc.
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Bristol-Myers Squibb Company
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 BellBrook Labs
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Enveda Biosciences
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Gilead Sciences, Inc.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 KITHER BIOTECH S.R.L.
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Verona Pharma plc
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Alpine Immune Sciences
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 Intercept Pharmaceuticals, Inc.
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
22.12 Teva Pharmaceutical Industries Ltd.
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisitions
22.12.5 Certifications
22.13 Sandoz International GmbH
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisitions
22.13.5 Certifications
22.14 Accord Healthcare
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisitions
22.14.5 Certifications
List not exhaustive
23 Fibrotic Diseases Treatment Treatment Drugs - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 7.8% during the forecast period of 2024-2032, the rising prevalence and incidence of fibrotic diseases across the 8 major markets.
The rapid advancement in the treatment of fibrotic diseases, growing preference for precision medicine, and heightened patient awareness are fuelling the demand for the market.
One of the significant trends in the market is the growth in clinical trials aimed at developing innovative and effective treatment therapies. In September 2023, Boehringer Ingelheim initiated the clinical development of its first-of-its-kind IL-11 inhibitor antibody, BI 765423, through a Phase 1 study. The objective of the trial is to evaluate the treatment's safety, tolerance, and pharmacokinetics in fibrotic diseases.
Based on the treatment type, the market is segmented into medication, organ transplantation, and oxygen therapy, among others.
Major end users of the market include hospitals, academic, and research institutes, among others.
Common applications areas include idiopathic pulmonary fibrosis (IPF), hepatic cirrhosis, renal fibrosis, cutaneous fibrosis, and others.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India.
Key players involved in the market are Genentech, Inc., Boehringer Ingelheim International GmbH, AbbVie Inc., Bristol-Myers Squibb Company, BellBrook Labs, Enveda Biosciences, Gilead Sciences, Inc., KITHER BIOTECH S.R.L., Verona Pharma plc, Alpine Immune Sciences, Intercept Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, and Accord Healthcare.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER